Lupin has reported results for fourth quarter (Q4) and year ended March 31, 2023.
The company has reported net profit of Rs 119.01 crore for the quarter under review as compared to net loss of Rs 35.89 crore for the same quarter in the previous year. Total income of the company increased by 0.70% at Rs 2,891.57 crore for Q4FY23 as compared to Rs 2,871.54 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported net profit of Rs 242.39 crore for fourth quarter ended March 31, 2023 as compared to net loss of Rs 511.73 crore for the same quarter in the previous year. Total income of the company increased by 14.59% at Rs 4,467.35 crore for Q4FY23 as compared to Rs 3,898.71 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported net profit of Rs 425.21 crore as compared to net loss of Rs 188.70 crore for the previous year. However, total income of the company decreased by 4.80% at Rs 11,350.09 crore for year under review as compared to Rs 11,922.09 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported net profit of Rs 447.69 crore as compared to net loss of Rs 1,509.36 crore for the previous year. Total income of the company increased by 1.01% at Rs 16,715.02 crore for year under review as compared to Rs 16,547.17 crore for year ended March 31, 2022.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: